Position in RPRX
as of Mar 31, 2026
· filed May 7, 2026
Position Value
$3,908,163
+$928,788 QoQ
Shares Held
81,471
+5.7% QoQ
Ownership
0.014%
of shares outstanding
% of Portfolio
0.02%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Dec 2022
9 quarters on record
Voting authority
Sole 100.ToString("F0")%
Shared 0.ToString("F0")%
None 0.ToString("F0")%
Common Shares in RPRX Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Mar 31, 2026AGF MANAGEMENT LTD holds $202,046,769 across 8 Biotechnology names. RPRX ranks #4 (1.9% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ARGX |
Argenx SE
|
125,069 | $91,331,637 | |
| 2 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
201,403 | $89,934,495 | |
| 3 | INSM |
INSMED Inc
|
57,458 | $9,395,532 | |
| 4 | RPRX |
Royalty Pharma plc
This page
|
81,471 | $3,908,163 | |
| 5 | INCY |
Incyte Corp
|
36,452 | $3,430,861 | |
| 6 | HALO |
Halozyme Therapeutics, Inc.
|
51,831 | $3,349,836 | |
| 7 | ZYME |
Zymeworks Inc.
|
15,000 | $375,600 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
415 | $320,645 |
All Filings in RPRX
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $3,908,163 | 81,471 | Shares | Sole | 2026-05-07 | |
| 2025-12-31 | $2,979,375 | 77,106 | Shares | Sole | 2026-02-17 | |
| 2025-09-30 | $3,219,722 | 91,262 | Shares | Sole | 2025-11-04 | |
| 2025-06-30 | $3,358,427 | 93,212 | Shares | Sole | 2025-08-06 | |
| 2025-03-31 | $2,505,341 | 80,480 | Shares | Sole | 2025-05-12 | |
| 2024-12-31 | $2,513,040 | 98,512 | Shares | Sole | 2025-02-07 | |
| 2024-03-31 | $505,873 | 16,657 | Shares | Sole | 2024-05-13 | |
| 2023-03-31 | $3,369,092 | 93,508 | Shares | Sole | 2023-05-02 | |
| 2022-12-31 | $3,138,677 | 79,420 | Shares | Sole | 2023-02-14 | |
| No filing history on record for this holder in this stock. | ||||||